TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01656252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I- Cytarabine & Eltrombopag
Description: Cycle 1= Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag (Open-Label) by mouth daily until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.~One cycle of consolidation therapy with high-dose cytarabine and eltrombopag will be received on study. Additional chemotherapy may be administered at the investigators discretion without eltrombopag.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II- Sequence A
Description: Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo by mouth daily with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II- Sequence B
Description: Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Placebo by mouth daily with 1st cycle of high-dose consolidation therapy and Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag.
Study: NCT00490490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexxar (tositumomab)
Description: Tositumomab is a CD20-directed radiotherapeutic (131-iodine) monoclonal antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed during or after rituximab therapy, including patients with rituximab-refractory non-Hodgkin's lymphoma. Tositumomab (standard regimen) will be administered at whole body exposure of 75 cGy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (XRT)
Description: Patient-specific XRT will begin within 24 hours of administration of the therapeutic dose of tositumomab. Subjects will receive local XRT to bulky sites of disease measuring at least 5 cm in at least one dimension. The size and number of fields to be treated will determined by the investigators, but will encompass the patient's most symptomatic/threatening site(s) of disease and not cumulatively include more than 25% of the active bone marrow. Subjects will be treated with the 2 x 2 Gy regimen (2 daily fractions of 2 Gy). Sites of disease previously-irradiated with 30 to 40 Gy will not be treated on this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Iodide (KI)
Description: Potassium iodide (KI) will be administered as:~* Saturated solution potassium iodide (SSKI) 4 drops orally 3-times-a-day,~* Lugol's solution 20 drops orally 3-times-a-day, OR~* KI tablets 130 mg orally once per day KI treatment will start at least 24 hours prior to tositumomab, and continue daily for 14 days following the last dose of tositumomab
Study: NCT04101318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Conformité Européene marked product
Description: New Baseplate is not named at this point

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Conformité Européene marked product
Description: New Baseplate is not named at this point

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conformité Européene marked competitor products
Description: The Conformité Européene marked competitor products are considered Standard of Care or products considered to be part of Standard of Care in coming years.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conformité Européene marked competitor products
Description: The Conformité Européene marked competitor products are considered Standard of Care or products considered to be part of Standard of Care in coming years.
Study: NCT03482466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Patients will be inside an MRI machine. They will be trained using real time feedback from brain imaging to learn personal strategies to bring their brain to the CALM state.
Study: NCT02022904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared (NIR) emissive nanotechnology
Study: NCT00162448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-394136
Description: Oral Solution, Oral, 100 mg, Single dose, 1 day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Single dose, 1 day.
Study: NCT00288184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol adminsitered one 200mg capsule by mouth twice daily. Placebo capsule once daily during crossover

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04229875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAG Bipolar
Description: See description of CAG Bipolar
Study: NCT04398290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Description: iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrogen gas
Description: 250 mcg/kg ideal body weight (IBW)/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen gas
Description: Supplemental oxygen administered via nasal cannula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: Supplemental oxygen administered via nasal cannula
Study: NCT02929329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil
Description: Omecamtiv mecarbil tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.
Study: NCT02885324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Subjects will receive Cabozantinib
Study: NCT00473265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH
Study: NCT01769768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafarin
Description: 15 mg single dose of warfarin (oral tablet) will be given to patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients
Study: NCT01470001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: solifenacin
Description: patient will receive solifenacin 5mg daily or placebo daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin
Description: patient will receive solifenacin 5mg daily or placebo daily
Study: NCT04688619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Program young In Favor of Myself, active parents
Description: Prevention program: young In Favor of Myself, with parent participation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevention Program young In Favor of Myself, no parental involvement
Description: Prevention program: young In Favor of Myself, without parent participation
Study: NCT04254822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt
Description: The TIPS procedures will be performed by experienced interventional radiologists. polytetrafluroethylene-covered stents were used with initial balloon dilatation to 8 mm, aiming for a decrease in portal-venous pressure gradient to less than 12 mm Hg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will be started at least 5 days after the index bleeding, unless a contraindication was present. Carvedilol will be start with 6.25 mg once a day and after 3 days increase to 6.25 mg twice-daily (the maximal dose was 12.5 mg/day). Systolic arterial blood pressure should not decrease \<90 mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol will be started at least 5 days after the index bleeding, unless a contraindication was present. Carvedilol will be start with 6.25 mg once a day and after 3 days increase to 6.25 mg twice-daily (the maximal dose was 12.5 mg/day). Systolic arterial blood pressure should not decrease \<90 mmHg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic variceal ligation
Description: For endoscopic variceal ligation, the first elective session will be carried out within 7 days of randomisation. Then EBL sessions were scheduled every 10-14 days until variceal eradication (disappearance of varices or being too small to be sucked in the banding device).
Study: NCT02530164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: active/sham tDCS as adjunctive treatment with a SSRI

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: active/sham tDCS as adjunctive treatment with a SSRI
Study: NCT03860636

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial thickness at ET
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial thickness at coordination scan
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial volume at HCG
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial volume at TVOR
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial volume at ET
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial volume at ET
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial volume at coordination scan
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for progesterone at HCG
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for progesterone at TVOR
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for progesterone at ET
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for progesterone at ET
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for progesterone at coordination scan
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: Change in endometrial pattern between TVOR and ET
Description: Ultrasound scan
Study: NCT04606771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib + Savolitinib
Description: Osimertinib 80 mg oral QD~Savolitinib 300mg oral QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib + Placebo
Description: Savolitinib 300mg Oral QD~Placebo to Osimertinib 80mg oral QD
Study: NCT03497416

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01698190

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound guided needle tissue acquisition.
Description: Endoscopic ultrasound with fine needle aspiration (FNA) allows for the safe and efficacious sampling of solid lesions that are in close proximity to the gastrointestinal tract, including extraintestinal masses, subepithelial tumors, and peri-intestinal lymphadenopathy. Fine needle core biopsy (FNB) has the potential of accruing larger tissue samples during biopsies, which may make the procedure more efficacious. In our study, we are comparing the overall efficacy between these two needles which are currently both used as standard of care.
Study: NCT03860636

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for estradiol at HCG
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for estradiol at TVOR
Description: Blood test
Study: NCT04357600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Umbilical Cord Mesenchymal Stem Cell
Description: All research samples will be treated by Intravenous injection of allogeneic mesenchymal stem cells and hemodynamic observation will be done for 24 hours after treated. Periodic post-treatment observation will be done on 1st month, 3rd month, and 6th month after therapy. The Independent variable in this research is Child-Pugh B Cirrhosis caused by Hepatitis B, while the dependent variable is the degree of liver function damage consisting of an examination of liver function, Child-Pugh score, and MELD score.
Study: NCT02797275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Beta agonist respiratory inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Beta agonist respiratory inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: respiratory inhaler with no medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: respiratory inhaler with no medication
Study: NCT00253084

Intervention type: DRUG
Group type: OTHER
Intervention: IPX054 200 mg
Description: IPX054 containing 50 mg carbidopa and 200 mg levodopa

Intervention type: DRUG
Group type: OTHER
Intervention: IPX054 200 mg
Description: IPX054 containing 50 mg carbidopa and 200 mg levodopa

Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD IR
Description: CD-LD IR containing 25 mg carbidopa and 100 mg levodopa

Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD IR
Description: CD-LD IR containing 25 mg carbidopa and 100 mg levodopa

Intervention type: DRUG
Group type: OTHER
Intervention: IPX054 Placebo
Description: Placebo to match IPX054 200 mg

Intervention type: DRUG
Group type: OTHER
Intervention: IPX054 Placebo
Description: Placebo to match IPX054 200 mg

Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD IR Placebo
Description: Placebo to match CD-LD IR

Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD IR Placebo
Description: Placebo to match CD-LD IR
Study: NCT01062802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80mg, once a day for four weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given once daily for 4 weeks.
Study: NCT02892695

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-NK cells
Description: The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD19 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD19.
Study: NCT03096080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Description: One dose of the study drug in liquid form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Description: One dose of the study drug in liquid form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Description: One dose of the study drug in liquid form
Study: NCT02435121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR125844
Description: Pharmaceutical form:Concentrate for solution Route of administration: intravenous
Study: NCT04059627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart Track
Description: Description of the device: Wearable heart rate sensors are used in Heart-track, and a receiver on a smartphone app. Real-time wireless heart rate data is sent to paired mobile device with a wireless distance of up to 10m. The sensor is able to monitor a heart rate range of 30 to 240 beats per minute.~Another component of Heart-track is a Heart-track mobile app which captures and reflect real-time heart rate from the heart rate sensor. The mobile app also includes warm-up and cool down exercises that are gamified and supported on a smart-phone running on Android or iOS platforms.~The HR sensor will be purchased by our collaborator, Immersive Play Pte Ltd.
Study: NCT01253304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Subcutaneous (SC) injection
Study: NCT01327495

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo acyline
Description: Placebo acyline subcutaneous injection every 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: daily placebo testosterone gel applied transdermally x 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone 1% gel 1.25 g
Description: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone 1% gel 2.5 g
Description: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone 1% gel 5.0 g
Description: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone 1% gel 10 g
Description: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone 1% gel 15 g
Description: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: 300 ug/kg subcutaneous injection every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: 300 ug/kg subcutaneous injection every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: 300 ug/kg subcutaneous injection every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: 300 ug/kg subcutaneous injection every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: 300 ug/kg subcutaneous injection every 2 weeks
Study: NCT02051959

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal stimulation of M1 + sham
Description: 8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area) followed by 8 sham treatments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham + Anodal stimulation of M1
Description: 8 sham treatments followed by 8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal stimulation of M1 + sham
Description: 8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area) , followed by 8 sham treatments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham + Cathodal stimulation of M1
Description: 8 sham treatments followed by 8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area).
Study: NCT02757040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib combined with As2O3
Description: arsenic trioxide combined with ibrutinib in CLL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibrutinib
Description: ibrutinib
Study: NCT01189175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113823 + Ketokonazole
Description: 5 days ketokonazole with single oral dose of BI 113823 on day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113823
Description: single oral dose
Study: NCT01503385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg by mouth twice daily for for 5-7 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 6 weeks).
Study: NCT00958503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamphenicol
Description: 750 and 1500 mg/day;tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched tablets without active ingredient
Study: NCT01854138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena Incision Management System
Description: Prevena Incision Management system will be applied to clean surgical wounds of patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty, immediately post-operatively. The unit will remain in place and functional for 7-8 days.
Study: NCT01353859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks for a total of 6 infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10-25 mg orally weekly